A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations
Open accessPublished version of a preprint
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
in a plaque-based live SARS-CoV-2 neutralization assay. The in vivo efficacy of the antibody is demonstrated in the Syrian hamster and in the human angiotensin-converting enzyme 2 (hACE2) mice model. The crystal structure of STE90-C11 Fab in complex with SARS-CoV-2-RBD is solved at 2.0 Å resolution showing that the antibody binds at the same region as ACE2 to RBD. The binding and inhibition of STE90-C11 is not blocked by many known emerging RBD mutations. STE90-C11-derived human IgG1 with FcγR-silenced Fc (COR-101) is undergoing Phase Ib/II clinical trials for the treatment of moderate to severe COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
Towards automated crystallographic structure refinement with phenix.refine
Afonine, P. V., Grosse-Kunstleve, R. W., Echols, N., Headd, J. J., Moriarty, N. W., Mustyakimov, M., Terwilliger, T. C., Urzhumtsev, A., Zwart, P. H., & Adams, P. D. (2012) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444912001308 · Cited by 5,511
Structural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661 · cited 1×
“This new human pathogenic coronavirus is closely related to the bat coronavirus RATG13, indicating an animal-to-human transition (Shang et al., 2020a).”
Cell entry mechanisms of SARS-CoV-2
Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A., & Li, F. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003138117 · Cited by 3,142
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
Wang, Q., Zhang, Y., Wu, L., Niu, S., Song, C., Zhang, Z., Lu, G., Qiao, C., Hu, Y., Yuen, K.-Y., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.045 · Cited by 2,892
Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Structural and functional analysis of a potent sarbecovirus neutralizing antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · doi:10.1101/2020.04.07.023903 · Cited by 1,752
Research works printed but not linked: 75
- Lundgren, 2021, A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19, N. Engl. J. Med., 384, 905, 10.1056/NEJMoa2033130 · DOI · Paper page
- Alfaleh, 2020, Phage Display Derived Monoclonal Antibodies: From Bench to Bedside, Front. Immunol., 11, 1986, 10.3389/fimmu.2020.01986 · DOI · Paper page
- Annavajhala, 2021, A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York, medRxiv
- Armour, 1999, Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities, Eur. J. Immunol., 29, 2613, 10.1002/(SICI)1521-4141(199908)29:08<2613::AID-IMMU2613>3.0.CO;2-J · DOI · Paper page
- Bertoglio, 2021, SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface, Nat. Commun., 12, 1577, 10.1038/s41467-021-21609-2 · DOI
- Boyerinas, 2015, Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells, Cancer Immunol. Res., 3, 1148, 10.1158/2326-6066.CIR-15-0059 · DOI · Paper page
- Bradbury, 2011, Beyond natural antibodies: the power of in vitro display technologies, Nat. Biotechnol., 29, 245, 10.1038/nbt.1791 · DOI · Paper page
- Brejová, 2021, B.1.258$∖Delta$, a SARS-CoV-2 variant with ΔH69/ΔV70 in the Spike protein circulating in the Czech Republic and Slovakia, arXiv
- Brünger, 1998, Crystallography & NMR system: a new software suite for macromolecular structure determination, Acta Crystallogr. D Biol. Crystallogr., 54, 905, 10.1107/S0907444998003254 · DOI · Paper page
- Burkhardt, 2016, Status of the crystallography beamlines at PETRA III, Eur. Phys. J. Plus, 131, 56, 10.1140/epjp/i2016-16056-0 · DOI
- Cao, 2020, Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells, Cell, 182, 73, 10.1016/j.cell.2020.05.025 · DOI · Paper page
- Chan, 1987, A novel tumour marker related to the c-myc oncogene product, Mol. Cell. Probes, 1, 73, 10.1016/0890-8508(87)90008-9 · DOI
- Chi, 2020, Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain, Nat. Commun., 11, 4528, 10.1038/s41467-020-18387-8 · DOI · Paper page
- Corti, 2016, Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody, Science, 351, 1339, 10.1126/science.aad5224 · DOI · Paper page
- Coughlin, 2012, Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential, Rev. Med. Virol., 22, 2, 10.1002/rmv.706 · DOI · Paper page
- Duan, 2009, Human Monoclonal Fab Antibodies Against West Nile Virus and its Neutralizing Activity Analyzed in Vitro and in Vivo, J. Antivir. Antiretrovir., 1, 36, 10.4172/jaa.1000005 · doi:10.4172/jaa.1000005
- Emsley, 2010, Features and development of Coot, Acta Crystallogr. D Biol. Crystallogr., 66, 486, 10.1107/S0907444910007493 · DOI · Paper page
- Evans, 2013, How good are my data and what is the resolution?, Acta Crystallogr. D Biol. Crystallogr., 69, 1204, 10.1107/S0907444913000061 · DOI · Paper page
- Frenzel, 2016, Phage display-derived human antibodies in clinical development and therapy, MAbs, 8, 1177, 10.1080/19420862.2016.1212149 · DOI · Paper page
- Frenzel, 2017, Designing Human Antibodies by Phage Display, Transfus. Med. Hemother., 44, 312, 10.1159/000479633 · DOI · Paper page
- Hodcroft, 2021, Emergence in late 2020 of multiple lineages of SARS-CoV-2 Spike protein variants affecting amino acid position 677, MedRxiv
- Huo, 2020, Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike, Cell Host Microbe, 28, 445, 10.1016/j.chom.2020.06.010 · DOI · Paper page
- Jäger, 2013, High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells, BMC Biotechnol., 13, 52, 10.1186/1472-6750-13-52 · DOI · Paper page
- Kabsch, 2010, XDS, Acta Crystallogr. D Biol. Crystallogr., 66, 125, 10.1107/S0907444909047337 · DOI · Paper page
- Korn, 2020, Baculovirus-free insect cell expression system for high yield antibody and antigen production, Sci. Rep., 10, 21393, 10.1038/s41598-020-78425-9 · DOI
- Kreer, 2020, Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients, Cell, 182, 843, 10.1016/j.cell.2020.06.044 · DOI · Paper page
- Kretzschmar, 2002, Antibody discovery: phage display, Curr. Opin. Biotechnol., 13, 598, 10.1016/S0958-1669(02)00380-4 · DOI
- Kügler, 2015, Generation and analysis of the improved human HAL9/10 antibody phage display libraries, BMC Biotechnol., 15, 10, 10.1186/s12896-015-0125-0 · DOI · Paper page
- Kügler, 2018, Construction of Human Immune and Naive scFv Libraries, Methods Mol. Biol., 1701, 3, 10.1007/978-1-4939-7447-4_1 · DOI
- Kuhn, 2016, Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display, Proteomics Clin. Appl., 10, 922, 10.1002/prca.201600002 · DOI
- Laemmli, 1970, Cleavage of structural proteins during the assembly of the head of bacteriophage T4, Nature, 227, 680, 10.1038/227680a0 · DOI · Paper page
- Li, 2020, High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models, Cell, 183, 429, 10.1016/j.cell.2020.09.007 · DOI · Paper page
- Liebschner, 2019, Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix, Acta Crystallogr. D Struct. Biol., 75, 861, 10.1107/S2059798319011471 · DOI · Paper page
- Liu, 2020, Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection, bioRxiv
- Lu, 2019, Deamidation and isomerization liability analysis of 131 clinical-stage antibodies, MAbs, 11, 45, 10.1080/19420862.2018.1548233 · DOI · Paper page
- Lu, 2020, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet, 395, 565, 10.1016/S0140-6736(20)30251-8 · DOI · Paper page
- Ma, 2021, Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain, J. Virol., 95, e02438-20, 10.1128/JVI.02438-20 · DOI
- McCoy, 2007, Phaser crystallographic software, J. Appl. Cryst., 40, 658, 10.1107/S0021889807021206 · DOI · Paper page
- Mulangu, 2019, A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics, N. Engl. J. Med., 381, 2293, 10.1056/NEJMoa1910993 · DOI · Paper page
- Nakamura, 2017, Effects of a mixture of medetomidine, midazolam and butorphanol on anesthesia and blood biochemistry and the antagonizing action of atipamezole in hamsters, J. Vet. Med. Sci., 79, 1230, 10.1292/jvms.17-0210 · DOI
- Nonaka, 2021, Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil, Emerg. Infect. Dis., 27, 1522, 10.3201/eid2705.210191 · DOI · Paper page
- Noy-Porat, 2020, A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes, Nat. Commun., 11, 4303, 10.1038/s41467-020-18159-4 · DOI · Paper page
- Osterrieder, 2020, Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters, Viruses, 12, 779, 10.3390/v12070779 · DOI · Paper page
- Parray, 2020, Identification of an anti-SARS-CoV-2 receptor-binding domain-directed human monoclonal antibody from a naïve semisynthetic library, J. Biol. Chem., 295, 12814, 10.1074/jbc.AC120.014918 · DOI
- Pascal, 2018, Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates, J. Infect. Dis., 218, S612, 10.1093/infdis/jiy285 · DOI · Paper page
- Rahumatullah, 2017, Antibody-Based Protective Immunity against Helminth Infections: Antibody Phage Display Derived Antibodies against BmR1 Antigen, Int. J. Mol. Sci., 18, 2376, 10.3390/ijms18112376 · DOI
- Ranjan, 2021, Bioinformatics analysis of SARS-CoV-2 RBD mutant variants and insights into antibody and ACE2 receptor binding, bioRxiv
- Rees-Spear, 2021, The effect of spike mutations on SARS-CoV-2 neutralization, Cell Rep., 34, 108890, 10.1016/j.celrep.2021.108890 · DOI · Paper page
- Resende, 2021, A potential SARS-CoV-2 variant of interest (VOI) harboring mutation E484K in the Spike protein was identified within lineage B.1.1.33 circulating in Brazil, Viruses, 13, 724, 10.3390/v13050724 · DOI
- Robert, 2014, Deciphering key features in protein structures with the new ENDscript server, Nucleic Acids Res., 42, W320, 10.1093/nar/gku316 · DOI · Paper page
- Rondot, 2001, A helper phage to improve single-chain antibody presentation in phage display, Nat. Biotechnol., 19, 75, 10.1038/83567 · DOI · Paper page
- Russo, 2018, Parallelized Antibody Selection in Microtiter Plates, Methods Mol. Biol., 1701, 273, 10.1007/978-1-4939-7447-4_14 · doi:10.1007/978-1-4939-7447-4_14
- Shields, 2001, High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R, J. Biol. Chem., 276, 6591, 10.1074/jbc.M009483200 · DOI · Paper page
- Soltes, 2007, On the influence of vector design on antibody phage display, J. Biotechnol., 127, 626, 10.1016/j.jbiotec.2006.08.015 · DOI
- Steinwand, 2014, The influence of antibody fragment format on phage display based affinity maturation of IgG, MAbs, 6, 204, 10.4161/mabs.27227 · DOI · Paper page
- Subramanian, 1998, Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group, Pediatr. Infect. Dis. J., 17, 110, 10.1097/00006454-199802000-00006 · DOI · Paper page
- Surleac, 2021, Evidence of Novel SARS-CoV-2 Variants Circulation in Romania. AIDS Res Hum Retroviruses, AIDS Res Hum Retroviruses, 37, 329, 10.1089/aid.2021.0009 · DOI
- Tian, 2020, Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody, Emerg. Microbes Infect., 9, 382, 10.1080/22221751.2020.1729069 · DOI · Paper page
- Trott, 2014, Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody, PLoS ONE, 9, e97478, 10.1371/journal.pone.0097478 · DOI
- van Mechelen, 2016, RSV neutralization by palivizumab, but not by monoclonal antibodies targeting other epitopes, is augmented by Fc gamma receptors, Antiviral Res., 132, 1, 10.1016/j.antiviral.2016.05.003 · DOI
- Walls, 2020, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein, Cell, 181, 281, 10.1016/j.cell.2020.02.058 · doi:10.1016/j.cell.2020.02.058 · Paper page
- Wan, 2020, Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry, J. Virol., 94, e02015-19, 10.1128/JVI.02015-19 · DOI · Paper page
- Wang, 2014, Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins, Biochem. Biophys. Res. Commun., 451, 208, 10.1016/j.bbrc.2014.07.090 · DOI · Paper page
- Wang, 2020, A human monoclonal antibody blocking SARS-CoV-2 infection, Nat. Commun., 11, 2251, 10.1038/s41467-020-16256-y · DOI · Paper page
- Wenzel, 2020, Human antibodies neutralizing diphtheria toxin in vitro and in vivo, Sci. Rep., 10, 571, 10.1038/s41598-019-57103-5 · DOI
- Wenzel, 2020, Antibody Phage Display: Antibody Selection in Solution Using Biotinylated Antigens, Methods Mol. Biol., 2070, 143, 10.1007/978-1-4939-9853-1_8 · doi:10.1007/978-1-4939-9853-1_8
- Wrapp, 2020, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, Science, 367, 1260, 10.1126/science.abb2507 · DOI · Paper page
- Wu, 2020, A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2, Science, 368, 1274, 10.1126/science.abc2241 · DOI · Paper page
- Yan, 2020, Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2, Science, 367, 1444, 10.1126/science.abb2762 · DOI · Paper page
- Yuan, 2020, A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV, Science, 368, 630, 10.1126/science.abb7269 · DOI · Paper page
- Zeng, 2020, Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy, Antib. Ther., 3, 95
- Zhang, 2003, Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library, J. Immunol. Methods, 283, 17, 10.1016/j.jim.2003.07.003 · DOI
- Zhou, 2020, Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2, Int. J. Biol. Sci., 16, 1718, 10.7150/ijbs.45123 · DOI · Paper page
- Zhou, 2020, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, 579, 270, 10.1038/s41586-020-2012-7 · DOI · Paper page
- Zhu, 2007, Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies, Proc. Natl. Acad. Sci. USA, 104, 12123, 10.1073/pnas.0701000104 · DOI · Paper page
Cited by
Monoclonal antibody therapies against SARS-CoV-2
Focosi, D., McConnell, S., Casadevall, A., Cappello, E., Valdiserra, G., & Tuccori, M. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00311-5 · Cited by 269
Chung, H.-Y., Wickel, J., Hahn, N., Mein, N., Schwarzbrunn, M., Koch, P., Ceanga, M., Haselmann, H., Baade-Büttner, C., von Stackelberg, N., et al. (2023) · Science Advances · doi:10.1126/sciadv.abq7806 · Cited by 156
“The assembly steps and anti-C1q mouse antibody production and purification were performed as previously described ( 57 , 58 ).”
Self-citationSequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain
Tan, T. J. C., Yuan, M., Kuzelka, K., Padron, G. C., Beal, J. R., Chen, X., Wang, Y., Rivera-Cardona, J., Zhu, X., Stadtmueller, B. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24123-7 · Cited by 75
Robinson, S. A., Raybould, M. I. J., Schneider, C., Wong, W. K., Marks, C., & Deane, C. M. (2021) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1009675 · Cited by 46
Azali, M. A., Mohamed, S., Harun, A., Hussain, F. A., Shamsuddin, S., & Johan, M. F. (2022) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-022-00368-7 · Cited by 13
Metadata
- Authors
- Bertoglio, F., Fühner, V., Ruschig, M., Heine, P. A., Abassi, L., Klünemann, T., Rand, U., Meier, D., Langreder, N., Steinke, S., Ballmann, R., Schneider, K.-T., Roth, K. D. R., Kuhn, P., Riese, P., Schäckermann, D., Korn, J., Koch, A., Chaudhry, M. Z., Eschke, K., Kim, Y., Zock-Emmenthal, S., Becker, M., Scholz, M., Moreira, G. M. S. G., Wenzel, E. V., Russo, G., Garritsen, H. S. P., Casu, S., Gerstner, A., Roth, G., Adler, J., Trimpert, J., Hermann, A., Schirrmann, T., Dübel, S., Frenzel, A., Van den Heuvel, J., Čičin-Šain, L., Schubert, M., & Hust, M.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 36
- Issue
- 4
- Pages
- 109433
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W3181438135
- Cited by
- 96
- References
- 27
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 1 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. https://app.cochat.ai/papers/10.1016/j.celrep.2021.109433
- The paper
- Bertoglio, F., Fühner, V., Ruschig, M., Heine, P. A., Abassi, L., Klünemann, T., Rand, U., Meier, D., Langreder, N., Steinke, S., Ballmann, R., Schneider, K.-T., Roth, K. D. R., Kuhn, P., Riese, P., Schäckermann, D., Korn, J., Koch, A., Chaudhry, M. Z., . . . Hust, M. (2021). A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. Cell Reports. https://doi.org/10.1016/j.celrep.2021.109433
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.